表紙
市場調査レポート

前立腺がん:パイプライン製品の分析

Prostate Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232770
出版日 ページ情報 英文 1596 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
前立腺がん:パイプライン製品の分析 Prostate Cancer - Pipeline Review, H2 2015
出版日: 2015年12月31日 ページ情報: 英文 1596 Pages
概要

前立腺がんは前立腺より発症する癌の一種で、男性、特に高齢の男性が罹患します。主な症状として、排尿時のトラブルや、尿を出す力の低下、血尿、腰・臀部・大腿部などの痛みなどが挙げられます。疾病素質には年齢や家族歴、肥満症などが含まれています。主な治療法には外科手術や化学療法、放射線治療などがあります。

当レポートでは、世界各国での前立腺がん治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

前立腺がんの概要

治療薬の開発

  • 前立腺がん向けパイプライン製品:概要
  • 前立腺がん向けパイプライン製品:比較分析

各企業で開発中の前立腺がん治療薬

大学/研究機関で研究中の前立腺がん治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

前立腺がん治療薬:開発中の製品の一覧(企業別)

前立腺がん治療薬:研究中の製品の一覧(大学/研究機関別)

前立腺がん治療薬の開発に従事している企業

  • Baxter International Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • 協和発酵キリン
  • Sanofi
  • AstraZeneca PLC
  • Viralytics Ltd.
  • GlaxoSmithKline plc
  • Bioniche Life Sciences, Inc.
  • Genentech, Inc.
  • 第一三共
  • Merck & Co., Inc.
  • 武田薬品工業
  • Amorfix Life Sciences Ltd.
  • Ipsen S.A.
  • MediGene AG
  • Bio-Path Holdings, Inc.
  • Jubilant Life Sciences Limited
  • ZIOPHARM Oncology, Inc.
  • Novartis AG
  • Samyang Holdings Corporation
  • アステラス製薬
  • GTx, Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Genmab A/S
  • Aduro BioTech, Inc.
  • Ferring International Center S.A.
  • Celgene Corporation
  • Bayer AG
  • AntiCancer, Inc.
  • Merck KGaA
  • Advaxis, Inc.
  • 4SC AG
  • Anavex Life Sciences Corp.
  • ValiRx Plc
  • AEterna Zentaris Inc.
  • Immunomedics, Inc.
  • Antisense Therapeutics Limited
  • Lorus Therapeutics Inc.
  • Bionomics Limited
  • Nymox Pharmaceutical Corporation
  • Oncothyreon Inc.
  • Compugen Ltd.
  • Patrys Limited
  • ArQule, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • ProMetic Life Sciences Inc.
  • Galectin Therapeutics, Inc.
  • Quest PharmaTech Inc.
  • Synta Pharmaceuticals Corp.
  • Natco Pharma Limited
  • Sareum Holdings plc
  • Oasmia Pharmaceutical AB
  • DiaMedica Inc.
  • Dongkook Pharmaceutical Co., Ltd.
  • Galena Biopharma, Inc.
  • Rexahn Pharmaceuticals, Inc.
  • Merrion Pharmaceuticals Plc.
  • Nanobiotix
  • Antigen Express, Inc.
  • Oryzon Genomics S.A.
  • Affitech A/S
  • Isarna Therapeutics GmbH
  • Colby Pharmaceutical Company
  • Mayne Pharma Group Limited
  • Chipscreen Biosciences Ltd
  • CIMAB S.A.
  • Fusion Antibodies Ltd.
  • Med Discovery SA
  • Pro-Cure Therapeutics Limited
  • immatics biotechnologies GmbH
  • LIDDS AB
  • Vaxon Biotech
  • Advantagene, Inc.
  • Medeia Therapeutics Ltd.
  • Aileron Therapeutics, Inc.
  • Alethia Biotherapeutics Inc.
  • GenSpera, Inc.
  • Ascenta Therapeutics, Inc.
  • Coronado Biosciences, Inc.
  • MacroGenics, Inc.
  • Provenance Biopharmaceuticals Corp.
  • Antyra, Inc.
  • Ambrx, Inc.
  • Pantarhei Bioscience BV
  • Azaya Therapeutics Incorporated
  • GP Pharm, S.A.
  • IC-MedTech, Inc.
  • Innate Therapeutics Limited
  • Iconic Therapeutics, Inc.
  • ProNAi Therapeutics, Inc.
  • Angion Biomedica Corp.
  • Axelar AB
  • Endocyte, Inc.
  • Omnitura Therapeutics Inc.
  • AndroScience Corporation
  • Pharminox Limited
  • Immutep S.A.
  • NovaLead Pharma Pvt. Ltd.
  • Esperance Pharmaceuticals, Inc.
  • Mirna Therapeutics, Inc.
  • Omeros Corporation
  • TransTech Pharma, Inc.
  • Immunovaccine, Inc.
  • Peptron, Inc.
  • Seek
  • Cellceutix Corporation
  • IGF Oncology, LLC
  • TVAX Biomedical, Inc.
  • Quintessence Biosciences, Inc.
  • Aprea AB
  • Biokine Therapeutics Ltd.
  • Cylene Pharmaceuticals, Inc.
  • Genelux Corporation
  • WntResearch AB
  • Viventia Biotechnologies Inc.
  • IRX Therapeutics, Inc.
  • Vicus Therapeutics, LLC
  • Oncovir, Inc.
  • Advanced Cancer Therapeutics
  • 3-V Biosciences, Inc.
  • Soricimed Biopharma Inc.
  • Almac Discovery Ltd.
  • VaxOnco Inc.
  • BHR Pharma, LLC
  • KAEL-GemVax Co., Ltd.
  • iCeutica, Inc.
  • Incuron, LLC
  • メビオファーム
  • Polaris Group
  • Vaccibody AS
  • DEKK-TEC, Inc.
  • Serometrix, LLC
  • CytoVac A/S
  • Acino Pharma AG
  • Sialix, Inc.
  • Bio-Cancer Treatment International Limited
  • APIM Therapeutics AS
  • EntreChem, S.L.
  • Cold Genesys, Inc.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Polyplus-transfection SA
  • Kancera AB
  • Vaxeal Holding SA
  • Arrien Pharmaceuticals, LLC
  • Qu Biologics Inc.
  • CZ BioMed Corp.
  • Evgen Limited
  • Activartis Biotech GmbH
  • Panacela Labs, Inc.
  • Avipep Pty Ltd
  • ATLAB Pharma SAS
  • Tactic Pharma, LLC
  • Kadmon Corporation, LLC
  • RAPID Pharmaceuticals AG
  • Akshaya Bio Inc.
  • ADC Therapeutics Sarl
  • Foresee Pharmaceuticals, LLC
  • Tolero Pharmaceuticals, Inc.
  • DexTech Medical AB
  • OncoNOx ApS
  • Curadis GmbH
  • PSites Pharma GmbH
  • Pharmedartis GmbH
  • DormaTarg, Inc.
  • Oncology Research International Limited
  • Galileo Research s.r.l.
  • Vasgen Limited
  • Balonco GMBH
  • SillaJen Co. Ltd.
  • Bionature E.A. Ltd.
  • TREAT U, S.A.

前立腺がん:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 酢酸アビラテロン
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • カバジタキセル
  • docetaxel-PM
  • デガレリクス
  • 酢酸ロイプロリドSR(徐放)
  • padeliporfin
  • 酢酸ロイプロリド
  • ProstAtak
  • 酢酸ロイプロリドの3ヶ月間投与
  • ozarelix
  • relugolix
  • MK-2206
  • アキシチニブ
  • テセモチド
  • ビタミンC+ビタミンK3
  • NX-1207
  • AE-37
  • Onyvax-P
  • teverelix
  • EP-100
  • チバンチニブ
  • DC-005
  • MVI-816
  • buparlisib hydrochloride
  • エトドラク+プロプラノロール
  • ジゴキシン
  • BV-NSCLC-001
  • CIMAvax-EGFペプチドワクチン
  • TVI-プロテアーゼ-1
  • IMMU-132
  • ヒドロキシフルタミド
  • MCS-8
  • Somadex
  • 精製イソフラボン
  • ドキソルビシン
  • APC-100
  • nelipepimut-S
  • CVA-21
  • SL-052
  • IMP-321
  • APR-246
  • 自家樹状細胞ワクチン
  • CC-223
  • ORCA-010
  • GSK-2636771
  • OPB-111001
  • EM-5854
  • GX-301
  • PSMA DNAワクチン
  • 前立腺がん向けワクチン
  • Immunocellgram For Cancer
  • Ad5-SGE-REIC/Dkk3遺伝子治療
  • パトリツマブ
  • HuMax-TF-ADC
  • MKC-1106-PP
  • MDPK-67b
  • HBI-8000
  • ドセタキセル・リポソーム
  • エストロゲン+プロゲステロン
  • KD-019
  • 抗酸菌性細胞膜DNA複合計画
  • tertomotide
  • DPX-0907
  • ONT-10
  • MER-104
  • 前立腺がん向けPSA標的細胞療法
  • 腫瘍向けNY-ESO-1標的ワクチン
  • pegargiminase
  • PEG-BCT-100
  • ALECSAT
  • GSK-2256098
  • PNT-2258
  • MIS-416
  • MGA-271
  • がん向けLSD-I阻害用小分子
  • ASP-1707
  • rhErbB3-f
  • GnRHm1-TTワクチン
  • トリプトレリンの3ヶ月投与
  • Foxy-5
  • SORC-13
  • Sulforadex
  • トリプトレリンの1ヶ月投与
  • 腫瘍向けムチン-1標的ワクチン
  • GLONC-4
  • Poly-ICLC
  • EC-1169
  • 腫瘍退縮性アデノウイルス療法
  • AEZS-120
  • BP-100-1.02
  • JG-0314
  • 前立腺がん向け治療薬
  • ATL-1101
  • KD-014
  • ADXS-PSA
  • 4SC-202
  • ドセタキセル
  • STA-9584
  • AXL-1717
  • CGEN-25008
  • CBL-0137
  • RX-0047N
  • ダリナパルシン
  • AB-16B5
  • ASC-JM.X2
  • ANAVEX-1037
  • OMN-54
  • トラベデルセン
  • Kevetrin
  • QBI-139
  • CVA21-DAFv
  • IRX-46
  • BNC-105
  • ATN-658
  • ANTG-12
  • AT-406
  • TTP-607
  • hI-con1
  • X-379
  • VAL-101
  • PU-27
  • EP-302
  • PGN-635
  • TF-12
  • ANAVEX-1519
  • MRX-34
  • PBI-1737
  • NRCAN-019
  • Adva-27a
  • RQ-00000008
  • G-115
  • TAK-114
  • EP-200
  • CX-6258
  • VBX-050
  • PMX-500
  • MBP-Y003
  • ALM-301
  • EC-7072
  • EC-7073
  • CEP-37440
  • nesvacumab
  • G-301
  • RX-21101
  • ADU-741
  • Vx-006
  • JX-1395
  • 乳がん・前立腺がん向け17β-HSD1型阻害薬
  • TALL-104
  • EC-1069
  • 腫瘍向けPFKFB-3阻害用小分子
  • GR-MD-02
  • ANAVEX-1066
  • VBX-008
  • MI-51964
  • Prorvlysis
  • INO-5150
  • AVP-6
  • 前立腺がん向けPTT-256標的モノクローナル抗体
  • EC-70124
  • AZD-1208
  • CNDO-109
  • FP-001
  • Mobilan
  • CG-0070-IT
  • IC-1206
  • BKT-150
  • ANG-3279
  • RAP-163
  • ATX-101
  • grapiprant
  • Rasstore
  • G-114
  • BAY-1001931
  • SORC-27
  • 腫瘍向け脂肪酸シンターゼ標的小分子
  • TP-3654
  • PSX-234
  • OX-1001
  • Sticky siRNA
  • ドセタキセル
  • インターロイキン13由来の遺伝子組み換え型タンパク質の送達
  • Pyrimidoaminotropanes
  • MEK-4阻害剤
  • Fsn-0503h
  • KBU-2046
  • 腫瘍向けNAMPT阻害用小分子
  • DT-310
  • DT-320
  • DT-330
  • 血管内皮拡張因子-165B
  • T-115
  • 前立腺がん向けAKR1C3阻害用小分子
  • インスリン様成長因子:メトトレキサート抱合体
  • STINGVAX
  • EP-300
  • CB-316
  • ADAM15阻害用モノクローナル抗体
  • イトラコナゾール
  • NBTX-TOPO
  • RI-EIP
  • 皮膚病・ホルモン障害・非悪性障害・腫瘍・婦人病向けGnRH受容体阻害薬
  • 腫瘍・中枢神経系(CNS)障害向け幹細胞治療
  • MPT0B-291
  • MDA-308プログラム
  • ATSP-9172
  • PMA-104R
  • PMA-204
  • Bromoacetoxycalcidol
  • 前立腺がん向けPSA阻害用モノクローナル抗体
  • SVX-1ワクチン
  • Vicrostatin
  • ADM-01
  • PSMAxCD3二重特異性抗体
  • A-5PE40
  • ORIL-007
  • レオウイルスの第一世代の弱毒株
  • 腫瘍向けSrcチロシンキナーゼ阻害用ペプチド
  • 乳がん・前立腺がん向け腫瘍退縮性単純ヘルペスウイルス
  • 乳がん・前立腺がん向け腫瘍退縮性単純ヘルペスウイルス(HSV)
  • 酢酸ロイプロリドの6ヶ月間投与
  • PAN-52
  • PLM-6
  • 前立腺がん向けワクチン
  • トリプトレリンパモ酸塩のバイオシミラー
  • ゴセレリンのバイオシミラー
  • 固形腫瘍向けDNA合成阻害用小分子
  • 婦人病・男性病・腫瘍向けGPR54標的合成ペプチド
  • 抗アンドロゲン・金ナノ粒子
  • Englerin A
  • ネズミチフス菌A1-R
  • 前立腺がん・肺腺病向けリソソーム酸セラミダーゼ
  • ORY-1001
  • LW-7
  • 前立腺がん向け抗体薬抱合体
  • BaxG-03
  • TF-011モノメチルオーリスタチンE
  • BaxB-01
  • BaxM-159
  • AMXT-1501+エフロルニチン
  • 前立腺がん・肺腺病向けPDGFRおよびVEGFR-2拮抗用小分子
  • 前立腺がん向け遺伝子組み換え型タンパク質
  • Project x-1670
  • S179D
  • MTDIA
  • ONC-2-13B
  • NSC-134754
  • がん向けMAPK・ER・AR阻害用エストロンのアナログ(類似体)
  • がん向けMAPK・AR阻害用ククルビタシンのアナログ(類似体)
  • 腫瘍向けペプチド
  • kbNB-14270
  • 抗EpCAM-IL2
  • AN-207
  • CR-1493
  • マルチロイシン・ペプチド
  • アシルフルベンの誘導体
  • AZA-1
  • MT-47100
  • パクリタキセル+PEG+アレンドロン酸
  • HPMA+パクリタキセル+アレンドロン酸
  • ARN-3236
  • Immunoplex 前立腺がん免疫療法
  • LLL-12
  • 前立腺がん向けPKB/Akt阻害剤
  • OSUA-9M
  • CC-2142
  • BO-2094
  • トランスフェリン抱合型Dendriplexes
  • CT-400P
  • VPE-001
  • JS-K
  • Glycerophospholipids
  • Peptide A-8R
  • IMA-962
  • KN-93
  • 前立腺がん向けPSCA標的ワクチン
  • CpG-STAT3 siRNA+CAR T細胞
  • Lm-LLO-PSA-HMWMAA
  • PCLN-201
  • DCBCI-0901
  • AT-201
  • VAL-401
  • KM-2812
  • SR-16388
  • C-1748
  • ADCT-401
  • ANAVEX-271041
  • 前立腺がん向けワクチン
  • 腫瘍向けVEGFR-3拮抗用小分子
  • 腫瘍向けFASN阻害用小分子
  • VAC-2
  • PAT-SM5
  • VLP-06
  • 腫瘍向けDNA標的小分子
  • 前立腺がん向けモノクローナル抗体
  • DM-204
  • 前立腺がん向け医薬品
  • AVP-4
  • 腫瘍・骨疾患・ぜんそく向けOGR1標的小分子
  • AMF-3d19
  • SX-ARPC
  • 前立腺がん向けJunD腫瘍性タンパク質・アンドロゲン受容体(AR)相互作用阻害用小分子
  • 腫瘍向けチューブリン阻害用小分子
  • APR-246のアナログ(類似体)
  • ZK-191784
  • QBECP SSI
  • 腫瘍向けEPHA2拮抗用遺伝子組み換え型タンパク質
  • 腫瘍向けROR-2阻害用小分子
  • Cytotoxamer
  • 前立腺がん向けナトリウムチャネル遮断用合成ペプチド
  • 前立腺がん向けナトリウムチャネル遮断用合成ペプチド2
  • 腫瘍向けBcl-2およびBcl-xL阻害用小分子
  • 腫瘍向けLPAおよびPI3K阻害用小分子
  • Delta 41-52 hPRL
  • 前立腺がんワクチン
  • 腫瘍向け小分子
  • 腫瘍向けEZH2-EED阻害用小分子
  • 4-aminocyclophosphamide
  • 前立腺がん向け腫瘍退縮性ウイルス
  • がん・PAH向け抗体
  • Cribrostatin-6
  • 腫瘍向けG9aメチルトランスファーゼ阻害用小分子
  • PLM-1
  • Astrogorgiadiol
  • 前立腺がん向けタンパク質
  • アンドロゲン受容体拮抗用薬剤
  • 腫瘍向けPancratistatin誘導体
  • 前立腺がん向けリガンド
  • 前立腺がん向けCYP17およびCYP11B2阻害用小分子
  • 腫瘍向けGARFT阻害用小分子
  • がん向けアンドロゲン受容体作動用薬剤
  • 腫瘍向けBcl-xおよびMCL-1阻害用ペプチド
  • 腫瘍向けBcl-xタンパク質およびMCL-1阻害剤
  • 腫瘍向けMISII型受容体活性化用小分子
  • ホルモン不応性前立腺癌向けアンドロゲン受容体阻害用小分子
  • OSUCG-12
  • TS-1
  • Alpha PSMA-ADC
  • がん向け脱ユビキチン化酵素修飾用小分子
  • がん向けメチル化環状ペプチド
  • 前立腺がん向け小分子
  • MAG-182
  • EVIRNA
  • がん向け前立腺・ホスタファーゼ標的ワクチン
  • 前立腺がん向け小分子
  • DN-1014
  • NBTXR-3
  • エストラジオール
  • AV0-113
  • がん向けSialyl-Tn標的モノクローナル抗体

前立腺がん治療薬:パイプライン製品の最新動向

前立腺がん治療薬:開発が休止状態の製品

前立腺がん治療薬:開発が中止された製品

前立腺がん関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7194IDB

Summary

Global Markets Direct's, 'Prostate Cancer - Pipeline Review, H2 2015', provides an overview of the Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Prostate Cancer Overview
  • Therapeutics Development
  • Prostate Cancer - Therapeutics under Development by Companies
  • Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Prostate Cancer - Pipeline Products Glance
  • Prostate Cancer - Products under Development by Companies
  • Prostate Cancer - Products under Investigation by Universities/Institutes
  • Prostate Cancer - Companies Involved in Therapeutics Development
  • Prostate Cancer - Therapeutics Assessment
  • Drug Profiles
  • Prostate Cancer - Recent Pipeline Updates
  • Prostate Cancer - Dormant Projects
  • Prostate Cancer - Discontinued Products
  • Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Prostate Cancer, H2 2015
  • Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Development by Companies, H2 2015 (Contd..12)
  • Number of Products under Development by Companies, H2 2015 (Contd..13)
  • Number of Products under Development by Companies, H2 2015 (Contd..14)
  • Number of Products under Development by Companies, H2 2015 (Contd..15)
  • Number of Products under Development by Companies, H2 2015 (Contd..16)
  • Number of Products under Development by Companies, H2 2015 (Contd..17)
  • Number of Products under Development by Companies, H2 2015 (Contd..18)
  • Number of Products under Development by Companies, H2 2015 (Contd..19)
  • Number of Products under Development by Companies, H2 2015 (Contd..20)
  • Number of Products under Development by Companies, H2 2015 (Contd..21)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Development by Companies, H2 2015 (Contd..19)
  • Products under Development by Companies, H2 2015 (Contd..20)
  • Products under Development by Companies, H2 2015 (Contd..21)
  • Products under Development by Companies, H2 2015 (Contd..22)
  • Products under Development by Companies, H2 2015 (Contd..23)
  • Products under Development by Companies, H2 2015 (Contd..24)
  • Products under Development by Companies, H2 2015 (Contd..25)
  • Products under Development by Companies, H2 2015 (Contd..26)
  • Products under Development by Companies, H2 2015 (Contd..27)
  • Products under Development by Companies, H2 2015 (Contd..28)
  • Products under Development by Companies, H2 2015 (Contd..29)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
  • Prostate Cancer - Pipeline by 4SC AG, H2 2015
  • Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
  • Prostate Cancer - Pipeline by AB Science SA, H2 2015
  • Prostate Cancer - Pipeline by AbbVie Inc., H2 2015
  • Prostate Cancer - Pipeline by Acino Pharma AG, H2 2015
  • Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
  • Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2015
  • Prostate Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
  • Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015
  • Prostate Cancer - Pipeline by Advantagene, Inc., H2 2015
  • Prostate Cancer - Pipeline by Advaxis, Inc., H2 2015
  • Prostate Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
  • Prostate Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Akshaya Bio Inc., H2 2015
  • Prostate Cancer - Pipeline by Alchemia Limited, H2 2015
  • Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
  • Prostate Cancer - Pipeline by Almac Discovery Limited, H2 2015
  • Prostate Cancer - Pipeline by Ambrx, Inc., H2 2015
  • Prostate Cancer - Pipeline by Amgen Inc., H2 2015
  • Prostate Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
  • Prostate Cancer - Pipeline by AndroScience Corporation, H2 2015
  • Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2015
  • Prostate Cancer - Pipeline by Angion Biomedica Corp., H2 2015
  • Prostate Cancer - Pipeline by AntiCancer, Inc., H2 2015
  • Prostate Cancer - Pipeline by Antigen Express, Inc., H2 2015
  • Prostate Cancer - Pipeline by Antisense Therapeutics Limited, H2 2015
  • Prostate Cancer - Pipeline by Aphios Corporation, H2 2015
  • Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2015
  • Prostate Cancer - Pipeline by Aptose Biosciences Inc., H2 2015
  • Prostate Cancer - Pipeline by Armour Therapeutics Inc., H2 2015
  • Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by ArQule, Inc., H2 2015
  • Prostate Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
  • Prostate Cancer - Pipeline by Arrowhead Research Corporation, H2 2015
  • Prostate Cancer - Pipeline by Arvinas, Inc., H2 2015
  • Prostate Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2015
  • Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2015
  • Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
  • Prostate Cancer - Pipeline by Avidity NanoMedicines, LLC, H2 2015
  • Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2015
  • Prostate Cancer - Pipeline by Axelar AB, H2 2015
  • Prostate Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
  • Prostate Cancer - Pipeline by Baxalta Incorporated, H2 2015
  • Prostate Cancer - Pipeline by Bayer AG, H2 2015
  • Prostate Cancer - Pipeline by Beta Pharma, Inc., H2 2015
  • Prostate Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015
  • Prostate Cancer - Pipeline by BHR Pharma, LLC, H2 2015
  • Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
  • Prostate Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2015
  • Prostate Cancer - Pipeline by Bionature E.A. Ltd., H2 2015
  • Prostate Cancer - Pipeline by Biotest AG, H2 2015
  • Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by Blirt S.A., H2 2015
  • Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Prostate Cancer - Pipeline by Camurus AB, H2 2015
  • Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd., H2 2015
  • Prostate Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by Celgene Corporation, H2 2015
  • Prostate Cancer - Pipeline by CellCentric Ltd, H2 2015
  • Prostate Cancer - Pipeline by Cellceutix Corporation, H2 2015
  • Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
  • Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2015
  • Prostate Cancer - Pipeline by Champions Oncology, Inc., H2 2015
  • Prostate Cancer - Pipeline by CohBar, Inc., H2 2015
  • Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2015
  • Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015
  • Prostate Cancer - Pipeline by Crescendo Biologics Limited, H2 2015
  • Prostate Cancer - Pipeline by CureVac GmbH, H2 2015
  • Prostate Cancer - Pipeline by CytoVac A/S, H2 2015
  • Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2015
  • Prostate Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
  • Prostate Cancer - Pipeline by DexTech Medical AB, H2 2015
  • Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
  • Prostate Cancer - Pipeline by DormaTarg, Inc., H2 2015
  • Prostate Cancer - Pipeline by Eisai Co., Ltd., H2 2015
  • Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2015
  • Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2015
  • Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2015
  • Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H2 2015
  • Prostate Cancer - Pipeline by EndoCeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Endocyte, Inc., H2 2015
  • Prostate Cancer - Pipeline by EntreChem, S.L., H2 2015
  • Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H2 2015
  • Prostate Cancer - Pipeline by Erytech Pharma SA, H2 2015
  • Prostate Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2015
  • Prostate Cancer - Pipeline by Eureka Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Evgen Pharma PLC, H2 2015
  • Prostate Cancer - Pipeline by Exonate Limited, H2 2015
  • Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Prostate Cancer - Pipeline by Ferring International Center S.A., H2 2015
  • Prostate Cancer - Pipeline by Forendo Pharma Limited, H2 2015
  • Prostate Cancer - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
  • Prostate Cancer - Pipeline by Fortress Biotech, Inc., H2 2015
  • Prostate Cancer - Pipeline by Fountain Biopharma Inc., H2 2015
  • Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2015
  • Prostate Cancer - Pipeline by G1 Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Galectin Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Galileo Research s.r.l., H2 2015
  • Prostate Cancer - Pipeline by Genelux Corporation, H2 2015
  • Prostate Cancer - Pipeline by Genentech, Inc., H2 2015
  • Prostate Cancer - Pipeline by Genmab A/S, H2 2015
  • Prostate Cancer - Pipeline by GenSpera, Inc., H2 2015
  • Prostate Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
  • Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2015
  • Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Prostate Cancer - Pipeline by GlycoMimetics, Inc., H2 2015
  • Prostate Cancer - Pipeline by GP Pharm, S.A., H2 2015
  • Prostate Cancer - Pipeline by GTx, Inc., H2 2015
  • Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
  • Prostate Cancer - Pipeline by Humanetics Corporation, H2 2015
  • Prostate Cancer - Pipeline by Huperion Sarl, H2 2015
  • Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2015
  • Prostate Cancer - Pipeline by IC-MedTech, Inc., H2 2015
  • Prostate Cancer - Pipeline by IGF Oncology, LLC., H2 2015
  • Prostate Cancer - Pipeline by Ignyta, Inc., H2 2015
  • Prostate Cancer - Pipeline by Immuneed AB, H2 2015
  • Prostate Cancer - Pipeline by Immunocore Limited, H2 2015
  • Prostate Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015
  • Prostate Cancer - Pipeline by Immunomedics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Immunovaccine, Inc., H2 2015
  • Prostate Cancer - Pipeline by Incanthera Ltd., H2 2015
  • Prostate Cancer - Pipeline by Incuron, LLC, H2 2015
  • Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2015
  • Prostate Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by Io Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Ipsen S.A., H2 2015
  • Prostate Cancer - Pipeline by Johnson & Johnson, H2 2015
  • Prostate Cancer - Pipeline by Jyant Technologies, Inc., H2 2015
  • Prostate Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
  • Prostate Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
  • Prostate Cancer - Pipeline by Kancera AB, H2 2015
  • Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Kite Pharma, Inc., H2 2015
  • Prostate Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
  • Prostate Cancer - Pipeline by Kura Oncology, Inc., H2 2015
  • Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • Prostate Cancer - Pipeline by Lidds AB, H2 2015
  • Prostate Cancer - Pipeline by Luye Pharma Group Ltd., H2 2015
  • Prostate Cancer - Pipeline by MacroGenics, Inc., H2 2015
  • Prostate Cancer - Pipeline by Meabco A/S, H2 2015
  • Prostate Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015

List of Figures

  • Number of Products under Development for Prostate Cancer, H2 2015
  • Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top